$BCLI recent development
1. FDA Authorizes Further NurOwn Dosing Under EAP.
2. FDA approved BrainStorm to manufacture NurOwn for the EAP at the Catalent facility.
3. Positive peer reviewed publication of NurOwn's Phase 3 Study for ALS.
4. Accelerating Access to Critical Therapies for ALS Act approved and signed.
5. Zacks Small Cap Research increased $BCLI valuation to $14.
1. FDA Authorizes Further NurOwn Dosing Under EAP.
2. FDA approved BrainStorm to manufacture NurOwn for the EAP at the Catalent facility.
3. Positive peer reviewed publication of NurOwn's Phase 3 Study for ALS.
4. Accelerating Access to Critical Therapies for ALS Act approved and signed.
5. Zacks Small Cap Research increased $BCLI valuation to $14.